Oxygenta [OXYGENTAPH] vs Sequent Scientific [SEQUENT] Detailed Stock Comparison
Oxygenta
BSE
Loading...
Sequent Scientific
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Oxygenta wins in 6 metrics, Sequent Scientific wins in 10 metrics, with 0 ties. Sequent Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Oxygenta | Sequent Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 444.32 | 153.95 | Sequent Scientific |
| Price-to-Book Ratio | N/A | 6.28 | N/A |
| Debt-to-Equity Ratio | -2.43 | 62.47 | Oxygenta |
| PEG Ratio | N/A | 1.29 | N/A |
| EV/EBITDA | -28.18 | 29.43 | Oxygenta |
| Profit Margin (TTM) | -13.45% | 1.85% | Sequent Scientific |
| Operating Margin (TTM) | -50.72% | 7.56% | Sequent Scientific |
| EBITDA Margin (TTM) | N/A | 7.56% | N/A |
| Return on Equity | 40.16% | 2.84% | Oxygenta |
| Return on Assets (TTM) | -12.44% | 1.37% | Sequent Scientific |
| Free Cash Flow (TTM) | $-87.89M | $442.73M | Sequent Scientific |
| 1-Year Return | 99.93% | 5.57% | Oxygenta |
| Price-to-Sales Ratio (TTM) | 2.69 | 2.76 | Oxygenta |
| Enterprise Value | $3.70B | $48.87B | Sequent Scientific |
| EV/Revenue Ratio | 3.31 | 3.05 | Sequent Scientific |
| Gross Profit Margin (TTM) | 4.52% | 46.86% | Sequent Scientific |
| Revenue per Share (TTM) | $31 | $64 | Sequent Scientific |
| Earnings per Share (Diluted) | $-2.86 | $1.15 | Sequent Scientific |
| Beta (Stock Volatility) | 0.56 | 0.91 | Oxygenta |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Oxygenta vs Sequent Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Oxygenta | -0.12% | -9.18% | -27.15% | -10.28% | -0.25% | -5.93% |
| Sequent Scientific | -0.15% | -0.44% | -6.77% | -2.09% | 9.71% | -5.23% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Oxygenta | 99.93% | 193.27% | 211.39% | 211.39% | 211.39% | 211.39% |
| Sequent Scientific | 5.57% | 52.75% | 30.80% | 19.46% | 19.46% | 19.46% |
Performance & Financial Health Analysis: Oxygenta vs Sequent Scientific
| Metric | OXYGENTAPH | SEQUENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.01B | ₹44.30B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 8,480 | 688,982 |
| 90 Day Avg. Volume | 4,887 | 534,520 |
| Last Close | ₹80.55 | ₹175.85 |
| 52 Week Range | ₹35.80 - ₹133.50 | ₹117.35 - ₹240.70 |
| % from 52W High | -39.66% | -26.94% |
| All-Time High | ₹133.50 (Jun 09, 2025) | ₹336.50 (Jun 28, 2021) |
| % from All-Time High | -39.66% | -47.74% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.20% | 0.13% |
| Quarterly Earnings Growth | 3.69% | 1.20% |
| Financial Health | ||
| Profit Margin (TTM) | -0.13% | 0.02% |
| Operating Margin (TTM) | -0.51% | 0.08% |
| Return on Equity (TTM) | 0.40% | 0.03% |
| Debt to Equity (MRQ) | -2.43 | 62.47 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹-7.15 | ₹28.19 |
| Cash per Share (MRQ) | ₹0.03 | ₹2.52 |
| Operating Cash Flow (TTM) | ₹-89,042,000 | ₹360.47M |
| Levered Free Cash Flow (TTM) | ₹-102,983,000 | ₹218.78M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Oxygenta vs Sequent Scientific
| Metric | OXYGENTAPH | SEQUENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 444.32 | 153.95 |
| Forward P/E | N/A | 35.06 |
| PEG Ratio | N/A | 1.29 |
| Price to Sales (TTM) | 2.69 | 2.76 |
| Price to Book (MRQ) | N/A | 6.28 |
| Market Capitalization | ||
| Market Capitalization | ₹3.01B | ₹44.30B |
| Enterprise Value | ₹3.70B | ₹48.87B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.31 | 3.05 |
| Enterprise to EBITDA | -28.18 | 29.43 |
| Risk & Other Metrics | ||
| Beta | 0.56 | 0.91 |
| Book Value per Share (MRQ) | ₹-7.15 | ₹28.19 |
Financial Statements Comparison: Oxygenta vs Sequent Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | OXYGENTAPH | SEQUENT |
|---|---|---|
| Revenue/Sales | ₹494.67M | ₹4.41B |
| Cost of Goods Sold | ₹472.30M | ₹2.35B |
| Gross Profit | ₹22.37M | ₹2.07B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-14.00M | ₹333.50M |
| EBITDA | ₹-13.51M | ₹505.30M |
| Pre-Tax Income | ₹-37.99M | ₹255.20M |
| Income Tax | ₹-16.46M | ₹79.50M |
| Net Income (Profit) | ₹-21.53M | ₹175.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | OXYGENTAPH | SEQUENT |
|---|---|---|
| Cash & Equivalents | ₹17,000 | ₹626.60M |
| Total Current Assets | ₹309.43M | ₹8.74B |
| Total Current Liabilities | ₹858.47M | ₹5.05B |
| Long-Term Debt | ₹215.22M | ₹3.00B |
| Total Shareholders Equity | ₹-256.41M | ₹7.70B |
| Retained Earnings | N/A | ₹1.25B |
| Property, Plant & Equipment | ₹368.30M | ₹2.84B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | OXYGENTAPH | SEQUENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | OXYGENTAPH | SEQUENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 8,480 | 688,982 |
| Average Daily Volume (90 Day) | 4,887 | 534,520 |
| Shares Outstanding | 36.98M | 249.89M |
| Float Shares | 2.30M | 117.77M |
| % Held by Insiders | 0.79% | 0.53% |
| % Held by Institutions | 0.00% | 0.13% |
Dividend Analysis & Yield Comparison: Oxygenta vs Sequent Scientific
| Metric | OXYGENTAPH | SEQUENT |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.00 |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | ₹0.00 |
| Ex-Dividend Date | N/A | N/A |